Nanjing King-Friend Biochemical Pharma

Nanjing King-Friend Biochemical Pharma is one of the...

• CSI 500.

Nanjing King-Friend Biochemical Pharma is a company listed under the stock ticker 603707 (CN).

View the org chart displaying its 7 main executives

Most searched biographies at Nanjing King-Friend Biochemical Pharma

• Yongqun Tang, Chairman of The Board and General Manager
• Juhua Xie, Director
• Guoqing Cui, Independent Director

Create your alert
to follow the executive moves at Nanjing King-Friend Biochemical Pharma.

Nanjing King-Friend Biochemical Pharma has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• MedMen has filed for bankruptcy protection  (posted on April 28 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma
• Lucia Aleotti - Director at Menarini Group

Learn more about the Pharmaceuticals industry >

Press releases by Nanjing King-Friend Biochemical Pharma

Social media about Nanjing King-Friend Biochemical Pharma

• Nanjing King-Friend Biochemical Pharma on Wikipedia, Google News & Yahoo Finance
• Nanjing King-Friend Biochemical Pharma on LinkedIn, Twitter & YouTube

Contact by email its executives including Xiwei Huang

Call Nanjing King-Friend Biochemical Pharma at +86 258...

View the org chart

Register to receive your alert

Report an error